Evidence map›Paper›PMID 30040737›Full record

ArticleJournal of Huntington's disease2018

Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders.

Karen E Anderson, Erik van Duijn, David Craufurd, Carolyn Drazinic, Mary Edmondson, Nathan Goodman, Daniel van Kammen, Clement Loy, Josef Priller, LaVonne Veatch Goodman

Open access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Huntington's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Psychosis in Huntington disease: a short update.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Insights into RNA-mediated pathology in new mouse models of Huntington's disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  17. Observational
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

Karen E AndersonDepartment of Psychiatry and Department of Neurology, Georgetown University, Washington, DC, USA.
Erik van DuijnDepartment of Psychiatry, Leiden University Medical Centre, Leiden; and Mental Health Care Centre Delfland, Delft, The Netherlands.
David CraufurdManchester Centre for Genomic Medicine, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Carolyn DrazinicChief Medical Officer of State Mental Health Facilities, Office of Substance Abuse and Mental Health Florida Department of Children and Families, Tallahassee, FL, USA.
Mary EdmondsonHD Reach, Raleigh, NC, USA.
Nathan GoodmanHuntington's Disease Drug Works, Seattle, WA, USA.
Daniel van KammenConsultant for CNS drug development, Professor emeritus University of Pittsburgh, Pittsburgh, PA, USA.
Clement LoyWestmead Huntington Disease Service, The University of Sydney, and the Garvan Institute of Medical Research, Sydney, Australia.
Josef PrillerDepartment of Neuropsychiatry, Charité - Universitätsmedizin, Berlin, Germany and University of Edinburgh and UK DRI, Edinburgh, UK.
LaVonne Veatch GoodmanHuntington's Disease Drug Works, Seattle, WA, USA.
Huntington University · USCharité - Universitätsmedizin Berlin · DEFlorida Department of Children and Families · USGeorgetown University · USLeiden University · NLManchester Academic Health Science Centre · GBThe University of Sydney · AUUniversity of Pittsburgh · US

Funding

Medical Research Council MC_PC_16031
6 · The paper itself

Abstract

backgroundIn clinical practice, several strategies and pharmacological options are available to treat neuropsychiatric symptoms of Huntington disease (HD). However, there is currently insufficient data for evidence-based guidelines on the management of these common symptoms.

objectiveWe aimed to develop expert-based recommendations regarding the management of agitation, anxiety, apathy, psychosis, and sleep disorders.

methodsGuideline development was based on a modified Institute of Medicine guideline process that accounted for a lack of evidence base. An international committee of 11 multidisciplinary experts proposed a series of statements regarding the description and management of each symptom. Statement assessment and validation was performed using a web-based survey tool and 84 international HD experts (neurologists and psychiatrists) who assessed the statements and indicated their level of agreement.

resultsHigh-level agreement (≥85% experts strongly agreed or agreed) was reached for 107 of the 110 statements that have been incorporated into the expert-based clinical recommendations presented herein.

conclusionsClinical statements to guide the routine management of agitation, anxiety, apathy, psychosis, and sleep disorders in HD have been developed. Although not specifically tested in the HD population, clinical experience has shown that most of the neuropsychiatric symptoms discussed, when considered in isolation are treatable using pharmacologic and non-pharmacologic strategies developed for use in other populations. However, the management of neuropsychiatric symptoms in HD can be complex because neuropsychiatric symptoms often co-exist and treatment decisions should be adapted to cover all symptoms while limiting polypharmacy.

Indexed as

AnxietyDisease ManagementHumansHuntington DiseasePractice Guidelines as TopicPrevalencePsychomotor AgitationPsychotic DisordersSleep Wake DisordersAgitationanxietyapathyclinical managementexpert opinionguidelinesHuntington diseasepsychosissleep disorders

Identifiers

PMID30040737
PMCPMC6294590
OpenAlexW2884386732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.